Abstract | PURPOSE: MATERIALS AND METHODS: We correlated somatic FGFR3-TACC3 fusions with clinical and molecular features in two cohorts of patients with bladder cancer. The first cohort consisted of the muscle-invasive bladder cancer (MIBC) data set (n = 412) from The Cancer Genome Atlas. The second cohort consisted of patients with MIBC or high-grade non-MIBC at the Dana-Farber Cancer Institute that had targeted capture sequencing of a selected panel of cancer genes (n = 356). All statistical tests were two sided. The clinical response of one patient with FGFR3-TACC3 bladder cancer to an FGFR3 inhibitor was investigated. RESULTS: Overall, 751 patients with high-grade bladder cancer without FGFR3-TACC3 fusions and 17 with FGFR3-TACC3 fusions were identified in the pooled analysis of the data sets from The Cancer Genome Atlas and the Dana-Farber Cancer Institute. FGFR3-TACC3 fusions were enriched in patients age ≤ 50 years versus age 51 to 65 years versus those older than 65 years (pooled, P = .002), and were observed in four (12%) of 33 patients age ≤ 50 years in the pooled analysis. Similarly, FGFR3-TACC3 fusions were significantly more common in Asians (13%) compared with African Americans (4%) and whites (2%; pooled, P < .001), as well as in never smokers (5.6%) compared with ever smokers (1.1%; pooled, P < .001). One patient with the fusion who was treated with an FGFR3 inhibitor achieved complete remission for 10 months. CONCLUSION: Clinical testing to identify FGFR3 fusions should be prioritized for patients with bladder cancer who are younger, never smokers, and/or Asian.
|
Authors | Amin H Nassar, Kevin Lundgren, Mark Pomerantz, Eliezer Van Allen, Lauren Harshman, Atish D Choudhury, Mark A Preston, Graeme S Steele, Kent W Mouw, Xiao X Wei, Bradley A McGregor, Toni K Choueiri, Joaquim Bellmunt, David J Kwiatkowski, Guru P Sonpavde |
Journal | JCO precision oncology
(JCO Precis Oncol)
Vol. 2
( 2018)
ISSN: 2473-4284 [Electronic] United States |
PMID | 33604498
(Publication Type: Journal Article)
|
Copyright | © 2018 by American Society of Clinical Oncology. |